Tuesday, November 23, 2021

Neurophth Gains $60M For Gene Therapy Efforts

San Diego-based Neurophth, a gene therapy company, has raised $60M in a Series C funding round, the company said today. The funding was co-led by CMG-SDIC Capital and Sequoia Capital China, and also included Sunshine Insurance and China Merchant Bank International Capital. According to the company, the funding will go towards its lead clinical program

The story you have requested is only available to paid members of the socalTECH.com web site. Premium articles are restricted to paid members only. Please login in order to access this members-only content, or become a member.